On Tuesday, Shares of RPC, Inc. (NYSE:RES), gained 4.18% to $10.23.
RPC Incorporated (RES), declared that it presented at the Barclay’s CEO Energy-Power Conference in New York City on Thursday, September 10, 2015 at 1:05 p.m. Eastern Time.
RPC, Inc. provides a range of oilfield services and equipment for oil and gas companies involved in the exploration, production, and development of oil and gas properties in the United States, Africa, Canada, China, Eastern Europe, Latin America, the Middle East, and New Zealand.
Shares of Rovi Corporation (NASDAQ:ROVI), inclined 1.75% to $11.61, during its last trading session.
Rovi Corporation and Nuance Communications, declared a joint initiative to deliver an end-to-end solution for conversational entertainment discovery. Nuance and Rovi will provide a fully integrated conversational voice interface that ultimately delivers a personalized entertainment experience where people can speak naturally to quickly and easily find and access content.
Nuance’s leading Dragon TV voice recognition, text-to-speech and voice biometrics will be integrated with Rovi’s unique, cloud-based Conversation Services. Together, Nuance and Rovi will enable device manufacturers and service providers to offer reliable and highly scalable voice interfaces that result in fast and relevant search and recommendations. In addition, the combined offering lowers a customer’s total cost of ownership, accelerates voice services deployment, and delivers compelling user experiences.
Rovi Corporation provides integrated solutions for the discovery and personalization of digital entertainment to service providers and consumer electronics (CE) industry worldwide. The company offers interactive program guides (IPGs), an interactive listing of television or video program information that enables viewers to navigate through, sort, select, and plan video programming for viewing and recording. It markets IPGs to service providers under i-Guide and Passport brands; and CE industry under the G-GUIDE and HTML Guide brands.
At the end of Tuesday’s trade, Shares of Tableau Software Inc (NYSE:DATA), lost -1.49% to $92.98.
Tableau Software, declared the general availability of Tableau 9.1, making it easier for people to analyze data from any source while in the office or on the go. New capabilities give people more ways to answer questions with data, an entirely new mobile experience, new options for connecting to data and easier security and authentication for the enterprise.
“Tableau 9.1 builds on our mission to assist people see and understand data, no matter where the data resides and what device they’re using,” said Chris Stolte, Chief Development Officer and co-founder of Tableau Software. “We’ve made noteworthy investments in enterprise features and an entirely new mobile app. We also created a web data connector that assists developers extend Tableau to connect to a limitless number of sources from Facebook to Twitter and Google Sheets. New native connectors to critical data sources such as SAP and Google Cloud SQL are also comprised.”
Tableau Software, Inc., together with its auxiliaries, provides business analytics software products in the United States, Canada, and internationally. The company offers Tableau Desktop, a self-service analytics environment that empowers people to access and analyze data independently; and Tableau Server, a business intelligence platform with data administration, scalability, and security to foster the sharing of data, in addition to to improve the dissemination of information in an organization and promote improved decision-making.
Finally, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), ended its last trade with 0.44% gain, and closed at $135.45.
Vertex Pharmaceuticals Incorporated, declared that administration will take part in a fireside chat at the Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 16th at 11:40 a.m. ET.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
